NewsEvents

Your Yourlocation: Home > Advances in clinical study of tiotropium bromide(136310-93-5) in the treatment of chronic obstructive pulmonary disease

From the treatment point of view, some bronchodilators may increase cardiac adverse reactions, such as leading to 65 years old of heart disease patients with abnormal heart; and, for example, theophylline and myocardial infarction. But other drugs do not cause serious cardiac side effects. Two large clinical trials on COPD drugs: UPLIFT (the Understanding Potential Long-Term Impactson Function with tiotropium bromide(136310-93-5) and TORCH (the Towardsa Revolutionin COPD Health studies) test showed that tiotropium bromide(136310-93-5) and salmeterol / fluticasone did not develop serious adverse cardiac reactions, respectively, according to Michele et al. reported that UPLIFT the data suggest that bronchodilators are safe in terms of cardiovascular and stroke, and that COPD patients should be treated with non-selective beta-blockers with caution because these drugs may worsen underlying bronchospasm.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved